Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts

References

• Mylius SD, Hagenaars TJ, Lugner AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine26(29–30), 3742–3749 (2008).
   PubMed Web of Science ®Google Scholar
• Gojovic MZ, Sander B, Fisman D et al. Modelling mitigation strategies for pandemic (H1N1) 2009. Can. Med. Assoc. J.181(10), 673–680 (2009).
   Web of Science ®Google Scholar
• Sander B, Nizam A, Garrison LP Jr et al. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health12(2), 226–233 (2009).
   PubMed Web of Science ®Google Scholar
• Sadique MZ, Adams EJ, Edmunds WJ. Estimating the costs of school closure for mitigating an influenza pandemic. BMC Public Health DOI: 10.1186/1471-2458-8-135 (2008) (Epub ahead of print).
   Google Scholar
• Siddiqui MR, Edmunds WJ. Cost–effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg. Infect. Dis.14(2), 267–274 (2008).
   PubMed Web of Science ®Google Scholar
• Keogh-Brown MR, Wren-Lewis S, Edmunds WJ et al.The Possible Macroeconomic Impact on the UK of an Influenza Pandemic. Department of Economics Discussion Paper Series 431, University of Oxford, Oxford, UK (2009).
   Google Scholar
• Smith RD, Keogh-Brown MR, Barnett T, Tait J. The economy-wide impact of pandemic influenza in the UK: a computable general equilibrium modeling experiment. Br. Med. J.339, b4571 (2009).
   PubMed Web of Science ®Google Scholar
• Keogh-Brown MR, Smith RD, Edmunds JW, Beutels P. The macro-economic impact of influenza: estimates from models of the United Kingdom, France, Belgium, and The Netherlands. Eur. J. Health Econ. DOI: 10.1007/s10198-009-0210-0211 (2009) (Epub ahead of print).
   Google Scholar
• Jonung L, Roeger W. The Macroeconomic Effects of a Pandemic in Europe – a Model-Based Assessment Economic Papers (no. 251). Directorate General Economic and Monetary Affairs, European Commission, Brussels, Belgium (2006).
   Google Scholar
• Congressional Budget Office of the US. A Potential Influenza Pandemic: Possible Macroeconomic Effects and Policy Issues. US Congress, Washington, DC, USA, (2006).
   Google Scholar
• van Genugten ML, Heijnen ML, Jager JC. Pandemic influenza and healthcare demand in The Netherlands: scenario analysis. Emerg. Infect. Dis.9(5), 531–538 (2003).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Bos JM, van Gennep M et al. Economic evaluation of influenza vaccination; assessment for The Netherlands. Pharmacoeconomics.16(Suppl. 1), 33–40 (1999).
   PubMed Web of Science ®Google Scholar
• Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature318(6044), 323–329 (1985).
   PubMed Web of Science ®Google Scholar
• Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg. Infect. Dis.5(5), 659–671 (1999).
   PubMed Web of Science ®Google Scholar
• Lugner AK, Mylius SD, Wallinga J. Dynamic versus static models in cost–effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ.19(5), 518–531 (2009).
   Google Scholar
• Welte R, Postma MJ, Leidl R, Kretzschmar M. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex. Transm. Dis.32(8), 474–483 (2005).
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Cummings DA, Fraser C et al. Strategies for mitigating an influenza pandemic. Nature442(7101), 448–452 (2006).
   PubMed Web of Science ®Google Scholar
• Longini IM Jr, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am. J. Epidemiol.161(4), 303–306 (2005).
   PubMed Web of Science ®Google Scholar
• Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc. Natl Acad. Sci. USA103(15), 5935–5940 (2006).
   PubMed Web of Science ®Google Scholar
• Lugner AK, Postma MJ. Investment decisions in influenza pandemic contingency planning: cost–effectiveness of stockpiling antiviral drugs. Eur. J. Public Health19(5), 516–520 (2009).
   PubMed Web of Science ®Google Scholar
• Khazeni N, Hutton D, Garber A et al. Effectiveness and cost–effectiveness of vaccination against pandemic influenza (H1N1). Ann. Intern. Med.151(12), 829–840 (2009).
   PubMed Web of Science ®Google Scholar
• Mossong J, Hens N, Jit M et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med.5(3), e74 (2008).
   PubMed Web of Science ®Google Scholar
• Milne G, Kelso J, Kelly H. Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines. J. R. Soc. Interface.7(45), 573–586 (2009).
   PubMedGoogle Scholar
• Leroux-Roels I, Bernhard R, Gerard P et al. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One3(2), e1665 (2008).
   PubMed Web of Science ®Google Scholar
• Kelso JK, Milne GJ, Kelly H. Simulation suggests that rapid activation of social distancing can arrest epidemic development due to a novel strain of influenza. BMC Public Health.9, 117 (2009).
   PubMedGoogle Scholar
• Milne GJ, Kelso JK, Kelly HA et al. A small community model for the transmission of infectious diseases: comparison of school closure as an intervention in individual-based models of an influenza pandemic. PLoS One3(12), e4005 (2008).
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA. Pneumococcal vaccines and flu preparedness. Science316(5821), 49–50 (2007).
   PubMedGoogle Scholar
• Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J. Health. Econ.14(2), 171–189 (1995).
   PubMed Web of Science ®Google Scholar
• Connolly MP, Pollard M, Hoorens S et al. Long-term economic benefits attributed to IVF-conceived children: a lifetime tax calculation. Am. J. Man. Care.14(9), 598–604 (2008).
   PubMed Web of Science ®Google Scholar
• Kaiser L, Wat C, Mills T et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med.163(14), 1667–1672 (2003).
   PubMed Web of Science ®Google Scholar
• Rothberg M, Rose D. Vaccination versus treatment of influenza in working adults: a cost–effectiveness analysis. Am. J. Med.118, 68–77 (2005).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect. Dis.8(9), 571–576 (2008).
   PubMedGoogle Scholar
• Haldar K. Targeting the host to control an infection disorder. Arch. Intern. Med.168(19), 2067–2068 (2008).
   PubMedGoogle Scholar
• Thomsen RW, Riis A, Kornum JB et al. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch. Intern. Med.168(19), 2081–2087 (2008).
   PubMed Web of Science ®Google Scholar
• Assink MD, Kiewiet JP, Rozenbaum MH et al. Excess drug prescriptions during influenza and RSV seasons in The Netherlands: potential implications for extended influenza vaccination. Vaccine27(7), 1119–1126 (2009).
   PubMedGoogle Scholar
• Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine28(11), 2356–2359(2009).
   PubMedGoogle Scholar
• Beutels P, Edmunds WJ, Smith RD. Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. Health Econ.17, 1317–1322 (2008).
   PubMedGoogle Scholar
• Lamers LM, Stalmeier PF, McDonnell J et al. [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff.] Ned. Tijdschr. Geneeskd.149(28), 1574–1578 (2005).
   PubMed Web of Science ®Google Scholar
• Nord E. Concerns for the worse off: fair innings versus severity. Soc. Sci. Med.60(2), 257–263 (2005).
   PubMed Web of Science ®Google Scholar
• Borba PS, Fitch K, Iwasaki K, Pyenson B. Pandemic influenza risk management for employers. Milliman Inc., NY, USA (2007).
   Google Scholar
• McKibbin W, Sidorenko A. Global Macroeconomic Consequences of Pandemic Influenza. Lowy Institute for International Policy, Sydney, Australia (2006).
   Google Scholar
• Grais RF, Ellis JH, Glass GE. Assessing the impact of airline travel on the geographic spread of pandemic influenza. Eur. J. Epidemiol.18(11), 1065–1072 (2003).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Baltussen RPM, Palache AM, Wilschut J. Further evidence for favorable cost–effectiveness of elderly influenza vaccination. Expert Rev. Pharmacoecon. Outcomes Res.6, 215–227 (2006).
   PubMedGoogle Scholar
• Lugnér AK, Postma MJ. Mitigation of pandemic influenza: review of cost–effectiveness studies. Expert Rev. Pharmacoecon. Outcomes Res.9, 547–558 (2009).
   PubMedGoogle Scholar
• de Vries R, van Bergen JE, de Jong-van den Berg LT, Postma MJ. Systematic screening for Chlamydia trachomatis: estimating cost–effectiveness using dynamic modeling and Dutch data. Value Health9(1), 1–11 (2006).
   PubMedGoogle Scholar
• Keogh-Brown MR, Smith RD. The economic impact of SARS: how does the reality match the predictions. Health Policy88(1), 110–120 (2008).
   PubMed Web of Science ®Google Scholar
• Sadique MZ, Edmunds WJ, Smith RD et al. Precautionary behavior in response to perceived threat of pandemic influenza. Emerg. Infect. Dis.13(9), 1307–1313 (2007).
   PubMed Web of Science ®Google Scholar